Hims & Hers Health (NYSE:HIMS) Stock Price Down 2.7%

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price traded down 2.7% during trading on Friday . The company traded as low as $17.03 and last traded at $17.23. 1,372,400 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 7,671,661 shares. The stock had previously closed at $17.71.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Jefferies Financial Group lifted their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. TD Cowen lifted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Truist Financial lifted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.86.

Hims & Hers Health Trading Down 0.9 %

The company has a market cap of $3.77 billion, a PE ratio of -1,771.00 and a beta of 1.05. The business’s 50 day moving average is $16.96 and its two-hundred day moving average is $17.13.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business’s quarterly revenue was up 51.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.03) EPS. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 45,767 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $16.33, for a total transaction of $747,375.11. Following the transaction, the chief executive officer now directly owns 67,015 shares in the company, valued at approximately $1,094,354.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Melissa Baird sold 17,625 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $20.51, for a total value of $361,488.75. Following the completion of the sale, the chief operating officer now owns 585,800 shares of the company’s stock, valued at approximately $12,014,758. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 45,767 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $16.33, for a total transaction of $747,375.11. Following the completion of the sale, the chief executive officer now directly owns 67,015 shares of the company’s stock, valued at approximately $1,094,354.95. The disclosure for this sale can be found here. Insiders have sold a total of 731,473 shares of company stock worth $12,671,277 in the last three months. Insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Hims & Hers Health by 164.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after acquiring an additional 328,142 shares during the last quarter. Cim LLC purchased a new position in shares of Hims & Hers Health in the second quarter worth $1,445,000. Sanctuary Advisors LLC purchased a new position in shares of Hims & Hers Health in the second quarter worth $415,000. Creative Planning purchased a new position in shares of Hims & Hers Health in the second quarter worth $443,000. Finally, Scientech Research LLC purchased a new position in shares of Hims & Hers Health in the second quarter worth $1,474,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.